BioNxt Announces Closing of Shares for Debt Settlement

Rhea-AI Summary

BioNxt (OTCQB:BNXTF) issued an aggregate of 6,008,883 common shares at a deemed price of $0.45 per share to settle $2,704,000 of debt (principal $2,600,000; accrued interest $104,000) from 8% convertible debentures dated December 7, 2022.

The company also issued 300,444 compensation shares to Canaccord Genuity Corp. at a deemed price of $0.63 per share for facilitating the debt settlement. All shares are subject to a statutory four-month-and-one-day hold period under Canadian securities laws.

Positive

• $2.704M of debt settled via equity issuance
• Debt settlement removes $2.6M principal from liabilities

Negative

• Issued 6,008,883 shares at $0.45, causing shareholder dilution risk
• Paid 300,444 compensation shares to advisor at $0.63, increasing dilution
• New shares subject to 4 months + 1 day hold, limiting liquidity

VANCOUVER, BC / ACCESS Newswire / February 26, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that, further to its news release dated January 23, 2026, the Company has issued an aggregate of 6,008,883 common shares in the capital of the Company (the "Debt Shares") at a deemed price of $0.45 per Debt Share to settle $2,704,000 in debt (the "Debt") owed to certain arm's length creditors (the "Debt Settlement"). The Debt was comprised of a principal amount of $2,600,000 and accrued interest of $104,000 pursuant to 8% convertible debentures issued by the Company on December 7, 2022.

In connection with the Debt Settlement, the Company issued 300,444 common shares in the capital of the Company (the "Compensation Shares") to Canaccord Genuity Corp. at a deemed price of $0.63 per Compensation Share as compensation for facilitating the Debt Settlement.

Each of the Debt Shares and the Compensation Shares are subject to a statutory four month and one day hold period in accordance with applicable Canadian securities laws.

About BioNxt Solutions Inc.

BioNxt Solutions Inc. is a bioscience innovator focused on next‐generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin‐Film), Transdermal (Skin Patch), and Oral (Enteric‐Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity. With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient‐centric solutions that enhance treatment outcomes worldwide.

BioNxt is listed on the Canadian Securities Exchange: BNXT, OTCQB Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.

Investor Relations & Media Contact

Hugh Rogers, Co‐Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 778.598.2698

Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt‐solutions
Instagram: https://www.instagram.com/bionxt

THIS NEWS RELEASE DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF ANY OFFER TO BUY, NOR SHALL THERE BE ANY SALE OF THESE SECURITIES IN ANY JURISDICTION IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL. THE SHARES ISSUED HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "U.S. SECURITIES ACT") AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS.

Neither the CSE nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

SOURCE: BioNxt Solutions Inc.

View the original press release on ACCESS Newswire

FAQ

What did BioNxt (BNXTF) announce on February 26, 2026 regarding debt settlement?

BioNxt issued 6,008,883 common shares to settle $2,704,000 of debt on February 26, 2026. According to the company, the Debt included $2,600,000 principal and $104,000 accrued interest from 8% convertible debentures dated December 7, 2022.

How many compensation shares did BioNxt (BNXTF) issue to Canaccord and at what price?

BioNxt issued 300,444 compensation shares to Canaccord at a deemed price of $0.63 per share. According to the company, these shares were issued as compensation for facilitating the Debt Settlement.

What is the deemed price and total value of the Debt Shares BioNxt (BNXTF) issued?

The Debt Shares were issued at a deemed price of $0.45 per share, totaling 6,008,883 shares. According to the company, those shares were issued to settle $2,704,000 of debt.

Are the shares issued by BioNxt (BNXTF) immediately tradable after issuance?

No. Each Debt Share and Compensation Share is subject to a statutory four-month-and-one-day hold period under Canadian securities laws. According to the company, this hold restricts resale for that period.

What debt instruments were settled by BioNxt (BNXTF) with the share issuance?

The company settled debt comprised of convertible debentures carrying 8% interest issued December 7, 2022. According to the company, the settlement covered $2,600,000 principal plus $104,000 accrued interest.